hristosbilis.ai Search

Search

Try Merck & Co.validationAnnex 22Discovery

    AI drug pipeline

    AI drug pipeline tracker

    Drugs that a public source explicitly says AI, machine learning or computational design helped discover or design, and where each one stands. Where a trial is registered, the card shows the phase from ClinicalTrials.gov. Where it isn't, the card shows what the company says and labels it that way.

    Inclusion rule: a drug is listed only if an online source explicitly says AI, machine learning or computational design was used to discover or design that specific drug, and its card links to that source. Each card names its AI source: a paper, the company or a post on X.Two cards are labeled exception (Zovegalisib and Lirafugratinib). They stay on the board although no source ties AI to them specifically.

    The pharma AI partner map shows who big pharma works with on AI, from drug discovery companies to AI platforms, health data groups and research centers.

    What big tech has announced in biology

    AI drug discovery company profiles

    Data as of . This section sits outside the Pharma AI Tracker, which records what large pharma companies say about their own AI work.

    Headline numbers

    • 40programs on the board
    • 17companies
    • 30in human trials or approved
    • 28with a trial registry record, any tier
    Programs per phase
    1. Preclinical 7 programs
    2. IND 3 programs
    3. Phase 1 20 programs
    4. Phase 2 4 programs
    5. Phase 3 5 programs
    6. Approved 1 program

    Combined phases count in the lower phase, so Phase 1/2 counts as Phase 1. 7 of 40 programs have a confirmed phase source from the company, a partner, a regulator or a paper. 24 rest on a trial registry record and 9 on a post on X only. The 28 with a trial registry record count every card that has one: the 24 registry cards plus 4 confirmed cards that also have a trial (GB-4362, ISM8969, Zasocitinib, Lirafugratinib). 40 of 40 link to an AI source: 9 to a paper, 31 to the company and 0 to a post on X.

    Pipeline board

    Showing 40 of 40 programs.

    Preclinical 7

    IND 3

    Phase 1 20

    Phase 2 4

    Phase 3 5

    Approved 1

    • Lirafugratinib (Lyrfigtu)

      Discovered by Relay Therapeutics. Developed by Elevar Therapeutics

      FDA approved, per FDA

      Treats: Previously treated unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement

      Modality
      Small molecule (FGFR2 inhibitor)
      AI role
      Computational design
      Inclusion
      Exception
      AI source
      Paper

      Discovered with Relay's Dynamo platform, using motion-based computational design (long-timescale molecular dynamics).

      Confirmed. Since

      Registry

    "Since" is the date of the dated source that reports the current phase. The phase may have started earlier.

    How to read the board

    • IND means an investigational new drug application, the filing a company makes before the first human trial. IND-enabling work counts as preclinical.
    • A "registry" label means the phase comes from the trial record on ClinicalTrials.gov. If the company's own post names a different phase, the card says so.
    • "Per company" means no trial record was found, so the phase is what the source post says.
    • Each card names how its phase source is backed. Confirmed means a primary official source: the company, a partner, a regulator or a paper. Registry means the phase comes from a ClinicalTrials.gov record. X only means the only source is a post on X.
    • "AI source" links to the strongest source that says AI, machine learning or computational design helped discover or design the drug. Paper means a peer-reviewed paper, Company means the developer's own release or page, and X means a post on X. The drug page quotes the AI wording.
    • Therapeutic areas are my grouping of the indication text. Programs with no stated indication sit under Other. Cards leave out a modality or indication the source does not give.

    Spot an error or a missing source? Tell me and I'll fix it.